COVID-19 Frontline

Supporting Patient Journeys Through Resources and Tools to Promote Positive Patient Outcomes in Care

Resource	Address
National Infusion Center Association. **COVID-19 Antibody Therapies Resource Center.** Accessed March 4, 2021.	https://infusioncenter.org/infusion_resources/covid-19-antibody-treatment-resource-center/
US Department of Health and Human Services. CombatCOVID. **Monoclonal Antibodies for High-Risk COVID-19 Positive Patients**. Accessed March 4, 2021.	https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients
Joost Wiersinga W, et al. **Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review.** *JAMA.* 2020;324:782-793.	https://pubmed.ncbi.nlm.nih.gov/32648899/
Guan WJ, et al. **Clinical characteristics of coronavirus disease 2019 in China.** *N Engl J Med*. 2020;382:1708-1720.	https://pubmed.ncbi.nlm.nih.gov/32109013/
Rothan HA, et al. **The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.** *J Autoimmun*. 2020;109:102433.	https://pubmed.ncbi.nlm.nih.gov/32113704/
Lechien JR, et al. **Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019.** *J Intern Med*. 2020;288:335-344.	https://pubmed.ncbi.nlm.nih.gov/32352202/
Wang W, et al. **Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China.** *J Med Virol*. 2020;92:441-447.	https://pubmed.ncbi.nlm.nih.gov/31994742/
Wu Z, et al. **Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention.** *JAMA*. 2020;323:1239-1242.	https://jamanetwork.com/journals/jama/fullarticle/2762130
Richardson S, et al. **Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.** *JAMA*. 2020;323:2052-2059.	https://pubmed.ncbi.nlm.nih.gov/32320003/
Docherty AB, et al. **Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study.** *BMJ.* 2020;369:m1985.	https://www.bmj.com/content/369/bmj.m1985
Yuan X, et al. **Changes of hematological and immunological parameters in COVID-19 patients.** *Int J Hematol*. 2020;112:553-559.	https://pubmed.ncbi.nlm.nih.gov/32656638/
Bhimraj A, et al. **Infectious Diseases Society of America (IDSA). IDSA Guidelines on the Treatment and Management of Patients with COVID-19**. V4.4.0. Updated February 22, 2021. Accessed March 4, 2021.	https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

Alhazzani W, et al. **Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19).** *Intensive Care Med*. 2020;46:854-887.	https://pubmed.ncbi.nlm.nih.gov/32222812/
World Health Organization (WHO). **Clinical management of COVID-19.** Interim Guidance. Published May 27, 2020. Accessed March 4, 2021.	https://www.who.int/publications/i/item/clinical-management-of-covid-19
National Institutes of Health (NIH). **Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.** Updated February 23, 2021. Accessed March 4, 2021.	https://www.covid19treatmentguidelines.nih.gov/
Beigel JH, et al. **Remdesivir for the treatment of COVID-19 – Final Report.** *N Engl J Med.* 2020;383:1813-1826.	https://www.nejm.org/doi/full/10.1056/NEJMoa2007764
Spinner CD, et al. **Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial.** *JAMA.* 2020;324:1048-1057.	https://jamanetwork.com/journals/jama/fullarticle/2769871
RECOVERY Collaborative Group, et al. **Dexamethasone in hospitalized patients with COVID-19.** *N Engl J Med.* 2021;384:693-704.	https://pubmed.ncbi.nlm.nih.gov/32678530/
Siddiqi HK, et al. **COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal.** *J Heart Lung Transplant.* 2020;39:405-407.	https://www.jhltonline.org/article/S1053-2498(20)31473-X/fulltext
Li L, et al. **Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial.** *JAMA*. 2020;324:460-470.	https://pubmed.ncbi.nlm.nih.gov/32492084/
Kalil AC, et al. **Baricitinib plus remdesivir for hospitalized adults with COVID-19.** *N Engl J Med.* 2021;384:795-807.	https://www.nejm.org/doi/full/10.1056/NEJMoa2031994
Baum A, et al. **Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.** *Science*. 2020;369:1014-1018.	https://pubmed.ncbi.nlm.nih.gov/32540904/
Gandhi RT, et al. **Mild or moderate COVID-19**. *N Engl J Med.* 2020;383:1757-1766.	https://pubmed.ncbi.nlm.nih.gov/32329974/
Docherty AB, et al. **Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study.** *BMJ.* 2020;369:m1985.	https://pubmed.ncbi.nlm.nih.gov/32444460/
Simonovich VA, et al. **A randomized trial of convalescent plasma in Covid-19 severe pneumonia.** *N Engl J Med*. 2020;384:619-629.	https://pubmed.ncbi.nlm.nih.gov/33232588/
US Food and Drug Administration (FDA). Fact Sheet for Health Care Providers. **Emergency Use Authorization (EUA) of Baricitinib.** Updated November 19, 2020. Accessed March 4, 2021.	https://www.fda.gov/media/143823/download

US Food and Drug Administration (FDA). Fact Sheet for Health Care Providers. **Emergency Use Authorization (EUA) of Bamlanivimab.** Updated February 9, 2021. Accessed March 4, 2021.	https://www.fda.gov/media/143603/download
US Food and Drug Administration (FDA). Fact Sheet for Health Providers. **Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab.** Issued February 9, 2021. Accessed March 4, 2021.	https://www.fda.gov/media/145802/download
US Food and Drug Administration (FDA). Fact Sheet for Health Care Providers. **Emergency Use Authorization (EUA) of Casirivimab and Imdevimab.** Revised December 2020. Accessed March 4, 2021.	https://www.fda.gov/media/143892/download
US Food and Drug Administration (FDA). Fact Sheet for Health Care Providers. **Emergency Use Authorization (EUA) of COVID-19 Convalescent Plasma for Treatment of Hospitalized Patients with COVID-19.** Updated February 4, 2021. Accessed March 4, 2021.	https://www.fda.gov/media/141478/download
Weinreich DM, et al. **REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-29.** *N Engl J Med.* 2021;384:238-251.	https://www.nejm.org/doi/pdf/10.1056/NEJMoa2035002
Gottlieb RL, et al. **Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial**. *JAMA*. 2021;325:632-644.	https://jamanetwork.com/journals/jama/fullarticle/2775647
Chen P, et al. **SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19.** *N Engl J Med.* 2021;384:229-237.	https://www.nejm.org/doi/full/10.1056/NEJMoa2029849
ACTIV-3/TICO LY-CoV555 Study Group, et al. **A neutralizing monoclonal antibody for hospitalized patients with COVID-19** [published online ahead of print, 2020 Dec 22]. *N Engl J Med.* 2020;NEJMoa2033130.	https://www.nejm.org/doi/full/10.1056/NEJMoa2033130
Hansen J, et al. **Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail**. *Science.* 2020;369:1010-1014.	https://science.sciencemag.org/content/369/6506/1010
Callaway E. **The coronavirus is mutating – does it matter?** *Nature.* 2020;585:174-177.	https://www.nature.com/articles/d41586-020-02544-6